Matheron Sophie, Damond Florence, Benard Antoine, Taieb Audrey, Campa Pauline, Peytavin Gilles, Pueyo Sophie, Brun-Vezinet Francoise, Chene Genevieve
Bichat Claude Bernard Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.
AIDS. 2006 Feb 14;20(3):459-62. doi: 10.1097/01.aids.0000199829.57112.2f.
In 61 antiretroviral-naive HIV-2-infected patients starting triple therapy at a median CD4 cell count of 136 cells/microl, the median increase was 41 cells/microl at month 12, which was no different among those on protease inhibitors or triple nucleoside analogues. Despite virological response, as the median plasma load was under the detectable threshold from month 3, CD4 cell recovery remained poor in treated HIV-2 infection. Our results raise the question of the optimal regimen to recommend in HIV-2-infected patients.
在61例未接受过抗逆转录病毒治疗、初次接受三联疗法的HIV-2感染患者中，其CD4细胞计数中位数为136个/微升，在第12个月时，中位数增加了41个/微升，这在接受蛋白酶抑制剂或三联核苷类似物治疗的患者中并无差异。尽管有病毒学反应，由于血浆载量中位数从第3个月起就低于可检测阈值，但在接受治疗的HIV-2感染患者中，CD4细胞恢复情况仍然较差。我们的研究结果提出了在HIV-2感染患者中推荐最佳治疗方案的问题。
